Abstract |
The outlook for patients with multiple myeloma (MM) has improved significantly with the development of new and more effective therapies, particularly the immunomodulatory agents and proteasome inhibitors. Preclinical and correlative science investigations have played a critical role in these advances, providing important insights regarding mechanisms of neoplasia, inhibition of tumor growth, and drug resistance. This review highlights the evolution of drug development in MM, the manner in which preclinical models have contributed to the process of drug discovery, and important insights gained during the current era of MM drug development.
|
Authors | Jacob Laubach, Teru Hideshima, Paul Richardson, Kenneth Anderson |
Journal | Seminars in oncology
(Semin Oncol)
Vol. 40
Issue 5
Pg. 549-53
(Oct 2013)
ISSN: 1532-8708 [Electronic] United States |
PMID | 24135399
(Publication Type: Journal Article, Review)
|
Copyright | © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Boronic Acids
- Proteasome Inhibitors
- Pyrazines
- Bortezomib
- Proteasome Endopeptidase Complex
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Boronic Acids
(therapeutic use)
- Bortezomib
- Drug Design
- Humans
- Mice
- Multiple Myeloma
(drug therapy, physiopathology)
- Proteasome Endopeptidase Complex
- Proteasome Inhibitors
(therapeutic use)
- Pyrazines
(therapeutic use)
- Treatment Outcome
|